• Welcome, Guest. Please login or register.
    December 14, 2019, 05:59:43 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2019





55167 Posts in 5879 Topics by 6159 Members
Latest Member: fatwhitepony

We love you, Lisa.
May you Rest in Peace,
knowing that your legacy lives on,
right here, and through all of us.
You're forever in our hearts.
« previous next »
Pages: 1 Go Down Print
Author Topic: REBLOZYL (Luspatercept) Approved by FDA  (Read 574 times)
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8608


Will thal rule you or will you rule thal?


« on: November 08, 2019, 03:40:51 PM »

Great news today! The new drug, REBLOZYL (Luspatercept) has been approved by the FDA today.

https://ir.celgene.com/press-releases/press-release-details/2019/FDA-Approves-REBLOZYL-luspatercept-aamt-for-the-Treatment-of-Anemia-in-Adults-With-Beta-Thalassemia-Who-Require-Regular-Red-Blood-Cell-Transfusions/default.aspx?fbclid=IwAR04eCT3kPgz4ysLirPWdIjmoFHGAWuu7omfB2hOT4ahZNct0U4r9s88lDw

Quote
REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy which works by regulating late-stage red blood cell maturation to help patients reduce their RBC transfusion burden.
REBLOZYL is anticipated to be available [in the US] 1 week following the FDA approval.

At this point, I do not know when it will become available outside the US, but I will try to inform once I know more.
Logged

Andy

All we are saying is give thals a chance.
Sunny2701
New Member
*
Offline Offline

Posts: 19


« Reply #1 on: November 10, 2019, 01:06:52 PM »

Great news! First Gene therapy approval and now this. This definatly is a big step forward. Let's hope everyone is able to reap benefits of these new modes of treatments as early as possible. Although this may not get us totally off transfusions, but there is a silver lining:)
Logged
anshul
New Member
*
Offline Offline

Posts: 22


« Reply #2 on: November 11, 2019, 08:16:17 AM »

Great News!!

Do we know if only Adults or Kids also can be benefited once it is available?
Logged
Emby
Senior Member
****
Offline Offline

Posts: 294


« Reply #3 on: November 11, 2019, 08:47:15 AM »

Thank you for this great news Andy!
Please can you help me to understand how exactly it works, although you have highlighted it.
I thought the Hb weakens when blood cells mature. Sorry mind fog. Will it be in medicine form?

Thank you and sorry just can't seem to think straight at the moment.
Logged
Sunny2701
New Member
*
Offline Offline

Posts: 19


« Reply #4 on: November 19, 2019, 02:56:53 AM »

Reblozyl will be available commercially in one week and will cost $3,441 per 25 mg vial at list price, the companies said. The drug is dosed by weight, typically at a dose of 1 milligram per kilogram.

For the recommended once per every three weeks regimen, that works out to an annual cost over $170,000 — "significantly higher" than expected, according to SVB Leerink analyst Geoffrey Porges.

Ref- https://www.biopharmadive.com/news/celgene-win-fda-approval-luspatercept-reblozyl-beta-thalassemia/566968/
Logged
Vikramjit Singh
New Member
*
Offline Offline

Posts: 1


« Reply #5 on: November 25, 2019, 04:29:37 AM »

Great news!
Logged
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8608


Will thal rule you or will you rule thal?


« Reply #6 on: November 26, 2019, 04:42:32 PM »

Not yet approved for children.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf

Quote
8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been established. Based on findings in
juvenile animals, REBLOZYL is not recommended for use in pediatric patients [see NonClinical Toxicology (13.1)].
Logged

Andy

All we are saying is give thals a chance.
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8608


Will thal rule you or will you rule thal?


« Reply #7 on: November 26, 2019, 04:45:59 PM »

Emby,

Reblozyl is an erythroid maturation agent. That means that it takes immature red blood cells that would not normally mature in thalassemics and it causes them to mature, adding to the RBC total and the Hb level. It is given as a subcutaneous injection every few weeks.
Logged

Andy

All we are saying is give thals a chance.
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!